Insmed Incorporated (Nasdaq:INSM) today reported financial results for the three and nine months ended September 30, 2014.
Highlights of the third quarter of 2014 include:
•Reported its U.S. regulatory strategy to initiate one global phase 3 confirmatory study of ARIKAYCE™, or liposomal amikacin for inhalation, for patients with nontuberculous mycobacterial (NTM) lung infections who failed prior standard of care treatment;
Help employers find you! Check out all the jobs and post your resume.
